|
Illumina, Inc. (ILMN) DCF -Bewertung
US | Healthcare | Medical - Diagnostics & Research | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Illumina, Inc. (ILMN) Bundle
Unser [ILMN] DCF-Taschenrechner für Genauigkeit entwickelt, ermöglicht es Ihnen, Illumina, Inc. unter Verwendung realer Finanzdaten zu bewerten und gleichzeitig vollständige Flexibilität bereitzustellen, um alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,239.0 | 4,526.0 | 4,584.0 | 4,504.0 | 4,372.0 | 4,769.2 | 5,202.5 | 5,675.1 | 6,190.7 | 6,753.1 |
| Revenue Growth, % | 0 | 39.73 | 1.28 | -1.75 | -2.93 | 9.09 | 9.09 | 9.09 | 9.09 | 9.09 |
| EBITDA | 767.0 | 747.0 | -3,916.0 | -608.0 | -725.0 | -718.5 | -783.8 | -855.0 | -932.6 | -1,017.4 |
| EBITDA, % | 23.68 | 16.5 | -85.43 | -13.5 | -16.58 | -15.06 | -15.06 | -15.06 | -15.06 | -15.06 |
| Depreciation | 187.0 | 251.0 | 394.0 | 432.0 | 354.0 | 358.7 | 391.3 | 426.8 | 465.6 | 507.9 |
| Depreciation, % | 5.77 | 5.55 | 8.6 | 9.59 | 8.1 | 7.52 | 7.52 | 7.52 | 7.52 | 7.52 |
| EBIT | 580.0 | 496.0 | -4,310.0 | -1,040.0 | -1,079.0 | -1,077.1 | -1,175.0 | -1,281.8 | -1,398.2 | -1,525.2 |
| EBIT, % | 17.91 | 10.96 | -94.02 | -23.09 | -24.68 | -22.59 | -22.59 | -22.59 | -22.59 | -22.59 |
| Total Cash | 3,472.0 | 1,339.0 | 2,037.0 | 1,054.0 | 1,220.0 | 2,149.3 | 2,344.5 | 2,557.5 | 2,789.9 | 3,043.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 487.0 | 648.0 | 688.0 | 752.0 | 735.0 | 742.7 | 810.2 | 883.8 | 964.1 | 1,051.7 |
| Account Receivables, % | 15.04 | 14.32 | 15.01 | 16.7 | 16.81 | 15.57 | 15.57 | 15.57 | 15.57 | 15.57 |
| Inventories | 372.0 | 431.0 | 568.0 | 587.0 | 547.0 | 562.2 | 613.3 | 669.0 | 729.8 | 796.1 |
| Inventories, % | 11.49 | 9.52 | 12.39 | 13.03 | 12.51 | 11.79 | 11.79 | 11.79 | 11.79 | 11.79 |
| Accounts Payable | 192.0 | 332.0 | 293.0 | 245.0 | 221.0 | 287.6 | 313.7 | 342.2 | 373.3 | 407.2 |
| Accounts Payable, % | 5.93 | 7.34 | 6.39 | 5.44 | 5.05 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 |
| Capital Expenditure | -189.0 | -208.0 | -466.0 | -195.0 | -128.0 | -265.7 | -289.8 | -316.1 | -344.9 | -376.2 |
| Capital Expenditure, % | -5.84 | -4.6 | -10.17 | -4.33 | -2.93 | -5.57 | -5.57 | -5.57 | -5.57 | -5.57 |
| Tax Rate, % | -3.73 | -3.73 | -3.73 | -3.73 | -3.73 | -3.73 | -3.73 | -3.73 | -3.73 | -3.73 |
| EBITAT | 444.5 | 427.5 | -4,377.6 | -1,081.0 | -1,119.3 | -997.1 | -1,087.7 | -1,186.5 | -1,294.3 | -1,411.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -224.5 | 390.5 | -4,665.6 | -975.0 | -860.3 | -860.5 | -1,078.7 | -1,176.7 | -1,283.6 | -1,400.2 |
| WACC, % | 8.29 | 8.35 | 8.44 | 8.44 | 8.44 | 8.39 | 8.39 | 8.39 | 8.39 | 8.39 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4,501.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,428 | |||||||||
| Terminal Value | -22,345 | |||||||||
| Present Terminal Value | -14,935 | |||||||||
| Enterprise Value | -19,437 | |||||||||
| Net Debt | 1,416 | |||||||||
| Equity Value | -20,853 | |||||||||
| Diluted Shares Outstanding, MM | 159 | |||||||||
| Equity Value Per Share | -131.15 |
What You Will Get
- Real ILMN Financial Data: Pre-filled with Illumina's historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Illumina's intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life ILMN Financials: Pre-filled historical and projected data for Illumina, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Illumina’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Illumina’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Get instant access to the Excel-based ILMN DCF Calculator.
- Input Your Assumptions: Adjust yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Illumina’s intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose This Calculator for Illumina, Inc. (ILMN)?
- Comprehensive Tool: Features DCF, WACC, and financial ratio analyses tailored for Illumina.
- Customizable Inputs: Modify highlighted cells to explore various financial scenarios for (ILMN).
- Detailed Insights: Automatically computes Illumina’s intrinsic value and Net Present Value.
- Preloaded Data: Access historical and forecasted data to ensure reliable starting points.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on (ILMN).
Who Should Use This Product?
- Investors: Evaluate Illumina’s valuation prior to making stock transactions.
- CFOs and Financial Analysts: Optimize valuation workflows and analyze future projections.
- Biotech Entrepreneurs: Understand how leading biotech firms like Illumina are appraised.
- Consultants: Provide comprehensive valuation reports for your clients.
- Students and Educators: Utilize real data to practice and instruct on valuation methodologies.
What the Template Contains
- Preloaded ILMN Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.